Insider · CIK 0001515813
Vipin K Garg
Files at ALT (Altimmune, Inc.). First filing -, latest -.
Vipin K Garg files SEC Form 4 as CEO, president and director at ALT (Altimmune, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Vipin K Garg has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 25 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +26,775 | $0.00 | $0 | 429,225 | Feb 2, 2026 |
| Jan 30, 2026 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -11,632 | $5.60 | $65k | 417,593 | Feb 2, 2026 |
| Jan 31, 2026 | ALT Altimmune, Inc. | AGrant or award Common Stock, par value $0.0001 | +6,926 | $3.07 | $21k | 424,519 | Feb 2, 2026 |
| Jan 30, 2026 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | -26,775 | $0.00 | $0 | 26,775 | Feb 2, 2026 |
| Jan 27, 2026 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +41,200 | $0.00 | $0 | 420,348 | Jan 29, 2026 |
| Jan 27, 2026 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -17,898 | $6.18 | $111k | 402,450 | Jan 29, 2026 |
| Jan 27, 2026 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | -41,200 | $0.00 | $0 | 123,600 | Jan 29, 2026 |
| Jan 25, 2026 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +42,050 | $0.00 | $0 | 397,132 | Jan 27, 2026 |
| Jan 25, 2026 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -17,984 | $5.50 | $99k | 379,148 | Jan 27, 2026 |
| Jan 25, 2026 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | -42,050 | $0.00 | $0 | 84,100 | Jan 27, 2026 |
| Jan 30, 2025 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +26,775 | $0.00 | $0 | 342,696 | Feb 3, 2025 |
| Jan 30, 2025 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -11,701 | $7.00 | $82k | 330,995 | Feb 3, 2025 |
| Jan 31, 2025 | ALT Altimmune, Inc. | AGrant or award Common Stock, par value $0.0001 | +4,105 | $5.18 | $21k | 335,100 | Feb 3, 2025 |
| Feb 1, 2025 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +16,545 | $0.00 | $0 | 351,645 | Feb 3, 2025 |
| Feb 1, 2025 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -7,231 | $6.64 | $48k | 344,414 | Feb 3, 2025 |
| Feb 2, 2025 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +18,950 | $0.00 | $0 | 363,364 | Feb 3, 2025 |
| Feb 2, 2025 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -8,282 | $6.64 | $55k | 355,082 | Feb 3, 2025 |
| Jan 30, 2025 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | +26,775 | $0.00 | $0 | 53,550 | Feb 3, 2025 |
| Feb 1, 2025 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | +16,545 | $0.00 | $0 | 0 | Feb 3, 2025 |
| Feb 2, 2025 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | +18,950 | $0.00 | $0 | 18,950 | Feb 3, 2025 |
| Jan 25, 2025 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +42,050 | $0.00 | $0 | 334,078 | Jan 28, 2025 |
| Jan 25, 2025 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -18,157 | $6.98 | $127k | 315,921 | Jan 28, 2025 |
| Jan 25, 2025 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | +42,050 | $0.00 | $0 | 126,150 | Jan 28, 2025 |
| Jan 27, 2025 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +477,500 | $0.00 | $0 | 477,500 | Jan 28, 2025 |
| Jan 27, 2025 | ALT Altimmune, Inc. | AGrant or award Restricted Stock Unitsderivative | +164,800 | $0.00 | $0 | 164,800 | Jan 28, 2025 |
Questions about Vipin K Garg
Answered from the filings on this page, as of the latest one.
Is Vipin K Garg buying or selling?
Vipin K Garg has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Vipin K Garg's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Vipin K Garg has 0.
Where does Vipin K Garg file Form 4?
Vipin K Garg has filed Form 4 at ALT (Altimmune, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.